These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 26812886)
21. Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation. Seidi K; Jahanban-Esfahlan R; Zarghami N Tumour Biol; 2017 Mar; 39(3):1010428317691001. PubMed ID: 28351332 [TBL] [Abstract][Full Text] [Related]
22. The development and use of vascular targeted therapy in ovarian cancer. Chase DM; Chaplin DJ; Monk BJ Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563 [TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Shaked Y; Kerbel RS Cancer Res; 2007 Aug; 67(15):7055-8. PubMed ID: 17671170 [TBL] [Abstract][Full Text] [Related]
24. Vascular-disrupting agents in oncology. Mita MM; Sargsyan L; Mita AC; Spear M Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880 [TBL] [Abstract][Full Text] [Related]
25. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments. Ji YT; Liu YN; Liu ZP Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094 [TBL] [Abstract][Full Text] [Related]
27. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors. Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008 [TBL] [Abstract][Full Text] [Related]
28. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Cai SX Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055 [TBL] [Abstract][Full Text] [Related]
29. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746 [TBL] [Abstract][Full Text] [Related]
30. Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment. Li B; Chu T; Wei J; Zhang Y; Qi F; Lu Z; Gao C; Zhang T; Jiang E; Xu J; Xu J; Li S; Nie G Nano Lett; 2021 Mar; 21(6):2588-2595. PubMed ID: 33650872 [TBL] [Abstract][Full Text] [Related]
31. Quantitating therapeutic disruption of tumor blood flow with intravital video microscopy. Iga AM; Sarkar S; Sales KM; Winslet MC; Seifalian AM Cancer Res; 2006 Dec; 66(24):11517-9. PubMed ID: 17178842 [TBL] [Abstract][Full Text] [Related]
32. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164 [TBL] [Abstract][Full Text] [Related]
33. Resistance to antiangiogenic therapies. Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752 [TBL] [Abstract][Full Text] [Related]